{'fraction_non_alphanumeric': 0.028178694158075602, 'fraction_numerical': 0.010996563573883162, 'mean_word_length': 4.432835820895522, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
THE ROLE OF LIPOPROTEIN (A) AND PREGNANCY ASSOCIATED PLASMA PROTEIN A IN DIAGNOSTICS CORONARY HEART DISEASE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

OBJECTIVE
The aim: To identify the significance of biomarkers characterizing the role of lipid disorders and the processes of destruction atherosclerotic plaque for the early diagnosis of CHD in patients with COPD.


PATIENTS AND METHODS
Materials and methods: There were examined 153 patients, men aged 40-70 years, including 53 patients with COPD, 56 with a combination of COPD and CHD and 44 patients with stable CHD. The level of LP (a) and PAPP-A in the serum was determined by ELISA.


RESULTS
Results: There was increased level of LP (a) and PAPP-A in patients with CHD and with a combination of COPD and CHD. This increased level of LP (a) and PAPP-A was associated with the level of C-reactive protein. The mid level of LP (a) and PAPP-A in patients with COPD did not significantly differ from the reference values.


CONCLUSION
Conclusions: The increase level of lipoprotein (a) more than 18 mg/dl in patients with COPD may be regarded as a predictor of the development of CHD. The level PAPP-A more than 5 mIU/L in plasma of patients with COPD makes it possible to isolate the groups for CHD risk. The definition of LP (a) and PAPP-A in patients with COPD may contribute to the early diagnostics of coronary heart disease in the absence of its pronounced clinical manifestations.